EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note


> Roche extended its antibody discovery and development collaboration with Discuva. The pact, which began in 2014, is now scheduled to run for another 12 months, bringing its total duration up to four years. Roche paid Discuva $16 million (€15 million) upfront, and committed to up to $175 million per product, when it signed the deal in 2014. Release

> Centauri Therapeutics closed a £2.5 million ($3.1 million) seed round. The British biotech capped off the round with a second £1.2 million tranche, giving it the means to move its lead anti-infective candidate to preclinical proof of concept. Centauri is also working on immuno-oncology targets through its joint venture with Horizon Discovery. Statement

> Modus Therapeutics raised SEK 32 million ($3.6 million). The Swedish biotech, which is part of the Karolinska Development stable, will use the money to complete its ongoing—and recently expanded—phase 2 trial of sevuparin in sickle cell disease. Data are due in the first half of next year. Release

> Neovacs struck a deal with Biosense for the Chinese rights to its anti interferon alpha therapeutic vaccine candidate. The deal will give Biosense regional rights to the vaccine in lupus and dermatomyositis once it successfully comes through a phase 2b. Biosense will pay up to €65 million ($68 million) in upfront and milestone fees, plus double-digit royalties, in return for the rights. Statement

> Apollo Therapeutics unveiled its first four drug discovery programs. The company, a collaboration between AstraZeneca, GlaxoSmithKline, Johnson & Johnson and three universities, has committed £8.5 million ($10.6 million) to projects emerging from academic centers in Cambridge and London. Treatments for alpha1 antitrypsin deficiency and retinal degeneration are among the four to secure funding. Release

> Cell Medica secured FDA fast-track status for its lead cancer immunotherapy. The candidate, CMD-003, is an autologous cell therapy designed to empower a patient’s T cells to target Epstein-Barr virus (EBV) epitopes. The FDA’s fast-track status covers use of the cell therapy in patients with relapsed or refractory lymphoma and post-transplant lymphoproliferative disease associated with oncogenic EBV. Statement